scholarly journals Evaluation on Lung Functions after Examination Stress in Student Population

2021 ◽  
pp. 225-234
Author(s):  
J. Noor Fathima ◽  
G. Sridevi ◽  
S. Preetha
Keyword(s):  
Lung Function ◽  
Academic Staff ◽  
Lung Function Test ◽  
The Body ◽  
Inverse Association ◽  
First Year Students ◽  
Learning Group ◽  
Lung Functions ◽  
Function Test ◽  
Examination Stress

Background: Professional degrees are daunting to the learning group because of a modern curriculum that is dramatically different from high school curricula and other educational courses. It is more pronounced among first year students in educational institutions because of rivalry and demands from institution managers, academic staff and parents. Stress causes many detrimental effects in the body. Aim: The present study planned to evaluate the effect of examination stress on the changes in lung functions among dental college students. Materials and Methods: 20 normal students were selected and categorised into normal and stressed students. They were assessed for a lung function test using RMS helios 702 Spirometer. The parameters such as FVC, FEV1, FEV1/FVC, PEFR, FEF25-75 were assessed. Results: It is observed that there was a decrease in the values of FVC, FEV1, FEV1/FVC, PEFR, FEF25-75 in exam stressed students when compared to normal students. The values of FEV1/FVC and FEF25-75 were statistically significant. Conclusion: Thus, the study concluded an innovative finding that there was an inverse association with depressive symptoms in the pulmonary function test of exam stressed students which was shown by a statistically significant decrease in FEV1/FVC and FEF25-75. Exam is really a stressful experience and affects both male and female students. Awareness should be conducted among students about ill effects of stress. Decreased stress, increased lung function results in increased academic performance.

scholarly journals Correlation of Cholinesterase Levels to Lung Function in Farmer Exposed by Organophosphate Pesticides in Sukorambi Village, Jember Regency

2019 ◽  
Vol 5 (2) ◽  
pp. 35
Author(s):  
Puput Sagita Mey Sandra ◽  
Kristianingrum Dian Sofiana ◽  
Ika Rahmawati Sutejo
Keyword(s):  
Lung Function ◽  
Significant Relationship ◽  
Lung Function Test ◽  
The Body ◽  
Plant Diseases ◽  
World Health ◽  
Organophosphate Pesticides ◽  
Cross Sectional ◽  
Agriculture Sector ◽  
Function Test

Abstract   Most of the Indonesia population work as a farmer. Pesticides are used in agriculture sector for pest and plant diseases. Pesticides can cause intoxication. The World Health Organization (WHO) estimates that 1-5 million cases of pesticides poisoning among agricultural workers occur in developing countries. Indonesia pesticide poisoning cases reach 771 cases. Organophosphate enter the body through inhalation. Organophosphate pesticides work systemic to inhibit the cholinesterase enzyme causing lung function disorders. The purpose of this study was to analyze the correlation of cholinesterase levels to lung function in farmers exposed to organophosphate pesticides in Sukorambi Village, Jember Regency. This is an observational analytic study using a cross sectional design. Cholinesterase levels test using the DGKC method to determine the presence of poisoning, while for lung function test using spirometry with FVC, FEV1 and FEV1 / FVC ratios as parameters. The results of the test  in 30 samples showed 14.33% (4/30) abnormal cholinesterase levels or decreased. Lung function test showed 20% (6/30) had obstructive disorders, 43.33% (13/30) restrictive disorders and 36.67% (11/30) were normal. Data analysis using chi square showed a significant relationship (p = 0.049) between cholinesterase levels and lung function. Conclusion: There is a significant relationship between the level of cholinesterase to decrease in pulmonary physiology of farmers exposed to organophosphate pesticides in Sukorambi Village, Jember Regency.   Keyword :Organophosphate, cholinesterase level, lung function  

Lung Function Test for Workers and its Quality Control Program

1994 ◽  
Vol 6 (2) ◽  
pp. 187
Author(s):  
Jung Keun Choi ◽  
Mi A Son ◽  
Hyun Kyung Kim ◽  
Domyung Paek ◽  
Byung Soon Choi
Keyword(s):  
Quality Control ◽  
Lung Function ◽  
Control Program ◽  
Lung Function Test ◽  
Quality Control Program ◽  
Function Test

AB0796 THE EVALUATION OF LUNG DIAGNOSTIC PROCEDURE AT THE ONSET OF INFLAMMATORY RHEUMATIC DISEASES WITH INTERSTITIAL LUNG DISEASE

2021 ◽  
Vol 80 (Suppl 1) ◽  
pp. 1422.3-1423
Author(s):  
T. Hoffmann ◽  
P. Oelzner ◽  
F. Marcus ◽  
M. Förster ◽  
J. Böttcher ◽  
...  
Keyword(s):  
Carbon Monoxide ◽  
Interstitial Lung Disease ◽  
Lung Function ◽  
Lung Disease ◽  
Sensitivity And Specificity ◽  
Lung Function Test ◽  
Inflammatory Rheumatic Diseases ◽  
X Ray ◽  
Function Test ◽  
Chest X Ray

Background:Interstitial lung disease (ILD) in inflammatory rheumatic diseases (IRD) is associated with increased mortality. Moreover, the lung is one of the most effected organs on IRD. Consequently, screening methods were required to the detect ILD in IRD.Objectives:The objective of the following study is to evaluate the diagnostic value of lung function test, chest x-ray and HR-CT of the lung in the detection of ILD at the onset of IRD.Methods:The study is designed as a case-control study and includes 126 patients with a newly diagnosed IRD. It was matched by gender, age and the performance of lung function test and chest x-ray. The sensitivity and specificity were verified by crosstabs and receiver operating characteristic (ROC) curve analysis. The study cohort was divided in two groups (ILD group: n = 63 and control group: n = 63). If possible, all patients received a lung function test and optional a chest x-ray. Patients with pathological findings in the screening tests (chest x-ray or reduced diffusing capacity for carbon monoxide (DLCO) < 80 %) maintained a high-resolution computer tomography (HR-CT) of the lung. Additionally, an immunological bronchioalveolar lavage was performed in the ILD group as gold standard for the detection of ILD.Results:The DLCO (< 80 %) revealed a sensitivity of 83.6 % and specificity of 45.8 % for the detection of ILD. Other examined parameter of lung function test showed no sufficient sensitivity as screening test (FVC = Forced Vital Capacity, FEV1 = Forced Expiratory Volume in 1 second, TLC = Total Lung Capacity, TLCO = Transfer factor of the Lung for carbon monoxide). Also, a combination of different parameter did not increase the sensitivity. The sensitivity and specificity of chest x-ray for the verification of ILD was 64.2 % versus 73.6 %. The combination of DLCO (< 80 %) and chest x-ray showed a sensitivity with 95.2 % and specificity with 38.7 %. The highest sensitivity (95.2 %) and specificity (77.4 %) was observed for the combination of DLCO (< 80 %) and HR-CT of the lung.Conclusion:The study highlighted that a reduced DLCO in lung function test is associated with a lung involvement in IRD. DLCO represented a potential screening parameter for lung manifestation in IRD. Especially patients with suspected vasculitis should receive an additional chest x-ray. Based on the high sensitivity of DLCO in combination with chest x-ray or HR-CT for the detection of ILD in IRD, all patients with a reduced DLCO (< 80%) should obtained an imaging of the lung.Disclosure of Interests:None declared

P21 Prescribing lvacaftor in paediatric patients with cystic fibrosis (cf) in accordance with the clinical commissioning policy in an nhs trust

2018 ◽  
Vol 103 (2) ◽  
pp. e1.26-e1
Author(s):  
McGeehan Eimear
Keyword(s):  
Cystic Fibrosis ◽  
Lung Function ◽  
Treatment Response ◽  
Membrane Conductance ◽  
Lung Function Test ◽  
Sweat Test ◽  
List Type ◽  
Adequate Treatment ◽  
Treatment Standard ◽  
Function Test

IntroductionCF is a genetic condition affecting more than 10 800 people in the UK. CF is caused by a mutation in the gene cystic fibrosis trans membrane conductance regulator (CFTR).Prior to the licensing of Ivacaftor, standard treatment for CF was to treat symptoms associated with CF but not the underlying cause. Ivacaftor targets the CFTR gene. Ivacaftor is funded by NHS England, if criteria outlined in the clinical commissioning policy is followed.1,2AimEnsure Ivacaftor is prescribed in adherence to guidance documented in the Clinical Commissioning Policy: Ivacaftor for CF (2012) and Clinical Commissioning Policy: Ivacaftor for children aged 2–5 years with CF, named mutations (2016).1,2Standards100% of Ivacaftor prescriptions will be for patients:2 years of age or olderHave a G55ID mutation100% of patients will receive lung function test (6 years and older) and baseline sweat test 6 months prior to commencing treatment100% of patients will receive a follow up sweat test/lung function test (6 years and older) at:Next routine appointment6 months after starting treatmentAnnually thereafter100% of patients who don’t attain an adequate treatment response will discontinue IvacaftorMethodRetrospective study investigated the prescribing of Ivacaftor in CF patients from March 2012 – June 2017 at an NHS trust. Ethics approval not required. List of patients prescribed Ivacaftor was obtained from the CF team. Patient age, mutation type, treatment start dates, lung function test results were obtained from medical notes. Dates and results of sweat tests were obtained from Sunquest ICE Desktop (electronic patient reporting system). Data analysed using Microsoft excel.ResultsEight patients prescribed Ivacaftor at the NHS trust between March 2012–June 2017. Baseline sweat chloride data unavailable for one patient who was previously part of a clinical trial. This patient was excluded from standard 2, however maintained for the other standards as his annual sweat data was available. One patient was excluded from standard 3(a), five patients excluded from standard 3 (b), (c) as they had not yet reached this stage of treatment. Standard 4 was not evaluated as all patients to date were responding to treatment. Overall, all standards were completely met with a result of 100%.Discussion and conclusionStandards were completely met; highlighting a robust system ensuring all appropriate testing is adhered to, as failure to comply with the criteria in the clinical commissioning policy may contribute to pressure within the trust’s budget. Treatment response can also be appropriately determined.RecommendationsEnsure data is inputted onto the system electronically.CF pharmacist to re–audit data yearly to ensure the clinical commissioning policy is being adhered to.ReferencesNHS Commissioning Board. Clinical commissioning policy: Ivacaftor for cystic fibrosis 2012. https://www. england.nhs.uk/wp-content/uploads/2013/04/a01-p-b.pdf [Accessed: 18th July 2017].NHS Commissioning Policy: Ivacaftor for children aged 2–5 years with cystic fibrosis (named mutations) 2016. https://www.england.nhs.uk/wp-content/uploads/2016/12/clin-comm-pol-16049P.pdf [Accessed: 18th July 2017].

Sign in / Sign up

Export Citation Format

Share Document